New paper on sulphonylureas in the therapy of diabetes mellitus type 2 patients published!
We analyzed anonymized data from a German health fund to compare all-cause mortality, major macrovascular events (MACE) and diabetes-related hospitalizations in T2DM-incident patients newly treated with metformin (MET) versus sulphonylureas (SU) monotherapy and in T2DM-prevalent patients newly treated with MET+SU versus MET+DDP4-inhibitor combination therapy. The obtained results show that SU monotherapy may be associated with increased mortality, MACE and T2DM hospitalizations, compared to MET monotherapy. When considering SU therapy, the associated cardiovascular risk should also be taken into account. Please refer to our open access paper for further details under the following link: http://jdmdonline.biomedcentral.com/articles/10.1186/s40200-016-0251-9